Search
Now showing items 1661-1670 of 1870
Hitting the Target: Developing High-quality Evidence for Proton Beam Therapy Through Randomised Controlled Trials.
(ELSEVIER SCIENCE LONDON, 2023-11-08)
The National Health Service strategy for the delivery of proton beam therapy (PBT) in the UK provides a unique opportunity to deliver high-quality evidence for PBT through randomised controlled trials (RCTs). We present a ...
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
(Elsevier BV, 2023-12-08)
Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis.
(NATURE PORTFOLIO, 2021-06-10)
Profiling studies have revealed considerable phenotypic heterogeneity in cancer-associated fibroblasts (CAFs) present within the tumour microenvironment, however, functional characterisation of different CAF subsets is ...
ESMO Guidance for Reporting Oncology real-World evidence (GROW).
(ELSEVIER, 2023-10-15)
The Role of ctDNA in Gastric Cancer.
(MDPI, 2022-10-18)
Circulating tumour DNA (ctDNA) has potential applications in gastric cancer (GC) with respect to screening, the detection of minimal residual disease (MRD) following curative surgery, and in the advanced disease setting ...
Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.
(AMER ASSOC CANCER RESEARCH, 2023-12-15)
Although the past decade has seen great strides in the development of immunotherapies that reactivate the immune system against tumors, there have also been major advances in the discovery of drugs blocking oncogenic drivers ...
ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C).
(BMC, 2023-03-20)
BACKGROUND: Circulating tumour DNA (ctDNA) to detect minimal residual disease (MRD) is emerging as a biomarker to predict recurrence in patients with curatively treated early stage colorectal cancer (CRC). ctDNA risk ...
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma.
(WILEY, 2021-11-01)
Bimiralisib is an orally bioavailable pan-phosphatidylinositol 3-kinase and mammalian target of rapamycin inhibitor which has shown activity against lymphoma in preclinical models. This phase I/II study evaluated the ...
Development and results of a patient-reported treatment experience questionnaire on a 1.5 T MR-Linac.
(ELSEVIER IRELAND LTD, 2021-09-01)
INTRODUCTION: With the implementation of new radiotherapy technology, it is imperative that patient experience is investigated alongside efficacy and outcomes. This paper presents the development of a specifically designed ...
Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland.
(BMC, 2020-05-06)
BACKGROUND: A randomised phase II trial demonstrated that the addition of olaratumab to doxorubicin significantly increased overall survival (OS) in patients with advanced soft tissue sarcomas (STS) compared to doxorubicin ...